Asia Pacific is home to more than half of the world’s population and bears a significant burden of infectious disease, particularly in the low-and-middle-income countries (LMICs) .

Hilleman Laboratories establishes pilot manufacturing facility for vaccine development in Singapore with support from Singapore Economic Development Board.